NR1H4 and metabolic dysfunction-associated steatohepatitis: As an example, OCA demonstrated first that FXR agonists can improve histopathology in NASH cases; however, at the 25 mg dosage, 51% of study participants reported pruritus compared to 19% in the placebo group, and 9% vs. <1% prematurely stopped treatment due to this side effect [7].